Status:
COMPLETED
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to...
Eligibility Criteria
Inclusion
- Are 20 years or older and considered to be candidates for systemic or phototherapy.
- \[Moderate to Severe Plaque Psoriasis\]
- Diagnosed for at least 12 months.
- Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis covering at least 10% of body surface area (BSA).
- \[Psoriatic Arthritis\]
- Diagnosed for at least 6 months.
- Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at screening;
- Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter.
Exclusion
- Non-plaque or drug induced forms of psoriasis
- Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (PUVA or UVB)
- any uncontrolled significant medical condition
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT01519089
Start Date
March 1 2012
End Date
January 1 2014
Last Update
August 13 2015
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan, 814-0180
2
Fukushima Medical University Hospital
Fukushima, Fukushima, Japan, 960-1295
3
JR Sapporo hospital
Sapporo, Hokkaido, Japan, 060-0033
4
Kobe University Hospital
Chuo-ku, Kobe, Hyōgo, Japan, 650-0017